Diagnostic preparations 1299
gadobutrol
Gadovist
Pregnancy risk category B3
Use in sport: Permitted
Available forms
Solution for injection:
604.72 mg/mL (1.0
mmol/mL) in 7.5 mL, 15 mL
Indications & dosages
➤
EnhancementofMRI—
Adultsandchildrenover2years:
0.1mmol/
kg bodyweight (0.1 mL/kg bodyweight) by
IV bolus.
Action
Diagnosticradiopharmaceuticalpreparation
that assists detection of altered perfusion in
areas of the cerebrum.
Route Onset
Peak
Duration
IV
Immediate Unknown 6 hrs
Adverse reactions
CNS:
convulsions, dizziness, dysgeusia,
headache,
loss of consciousness
, tremor.
CV:
cardiac arrest
,
circulatory failure
,
hypertension, hypotension, pallor, palpi
tations, tachycardia.
Eye:
conjunctivitis, oedema of eyelids.
GI:
dry mouth, nausea, vomiting.
GU:
acute kidney injury
.
Respiratory:
bronchospasm
, cough,
cyanosis, dyspnoea, laryngeal oedema,
oropharyngeal oedema
,
pulmonary
oedema
, sneezing.
Musculoskeletal:
nephrogenic systemic
fibrosis
.
Skin:
erythema, facial oedema, flushing,
rash, pruritus, urticaria.
Other:
anaphylactic reaction
, hyper
sensitivity, injection site reaction, malaise.
Interactions
None reported.
Contraindications
Contraindicated in individuals with known
hypersensitivity to the preparation.
care considerations
• Increased risk of nephrogenic systemic
fibrosis in individuals with acute or chronic
renal failure or acute renal insufficiency,
or during the perioperative period in liver
transplantation. Renal function should
be assessed in all individuals prior to the
procedure.
• For individuals on chronic haemodialysis,
initiate haemodialysis promptly following
administration of gadobutrol to increase
elimination.
• Closelymonitor individualfordevelopment
of anaphylactic reaction. Ensure emergency
management equipment is available and in
correct working order.
• Monitor vital signs closely following
procedure.
• If there is a need to repeat administration,
there should be at least 7 hours between
doses.
Patient teaching
• Advise person to report any adverse
effects.
gadodiamide
Omniscan
Pregnancy risk category B3
Use in sport: Permitted
Available forms
Solutionfor injection:
287mg/mL (0.5mmol/
mL) in 5 mL, 10 mL, 15 mL, 20 mL in vials,
ampoules and prefilled syringes
Indications & dosages
➤
EnhancementofCNSorwhole-bodyMRI—
Adultsandchildrenover2years:
0.1mmol/
kg bodyweight (0.2 mL/kg bodyweight) by
IV bolusor infusionupto100kgbodyweight.
Above 100 kg bodyweight, 20 mL is usually
sufficient.
